KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Amneal Pharmaceuticals (AMRX) Accumulated Depreciation & Amortization (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 8 years of Accumulated Depreciation & Amortization data on record, last reported at $563.5 million in Q4 2024.

  • For Q4 2024, Accumulated Depreciation & Amortization rose 10.92% year-over-year to $563.5 million; the TTM value through Dec 2024 reached $563.5 million, up 10.92%, while the annual FY2024 figure was $563.5 million, 10.92% up from the prior year.
  • Accumulated Depreciation & Amortization reached $563.5 million in Q4 2024 per AMRX's latest filing, up from $508.0 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $563.5 million in Q4 2024 and bottomed at $332.1 million in Q4 2020.
  • Average Accumulated Depreciation & Amortization over 5 years is $448.8 million, with a median of $446.0 million recorded in 2022.
  • Peak YoY movement for Accumulated Depreciation & Amortization: grew 20.32% in 2020, then grew 10.92% in 2024.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $332.1 million in 2020, then increased by 18.79% to $394.6 million in 2021, then rose by 13.03% to $446.0 million in 2022, then increased by 13.91% to $508.0 million in 2023, then rose by 10.92% to $563.5 million in 2024.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $563.5 million in Q4 2024, $508.0 million in Q4 2023, and $446.0 million in Q4 2022.